Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $3.5 million.

  • Voyager Therapeutics' Share-based Compensation rose 75.71% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 644.96%. This contributed to the annual value of $14.8 million for FY2024, which is 3256.52% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Share-based Compensation stood at $3.5 million, which was up 75.71% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Share-based Compensation peaked at $4.1 million during Q2 2025, and registered a low of $1.7 million during Q4 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $3.0 million (2023), whereas its average is $3.0 million.
  • In the last 5 years, Voyager Therapeutics' Share-based Compensation crashed by 5276.98% in 2021 and then skyrocketed by 5127.25% in 2024.
  • Voyager Therapeutics' Share-based Compensation (Quarter) stood at $1.7 million in 2021, then surged by 41.84% to $2.3 million in 2022, then increased by 29.8% to $3.0 million in 2023, then increased by 22.73% to $3.7 million in 2024, then fell by 7.41% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $4.1 million for Q2 2025, and $3.7 million during Q1 2025.